NovoCure Ltd treatment gains FDA approval for pancreatic cancer

Traders Union
All News
Companies
FDA approves NovoCure treatment

Top Stories

Editors' Picks

Crypto

Financial News

Currencies

Market Voices

Companies

Regulators

Central Banks

Olesia Kramarenko

12.02.2026

NovoCure Ltd treatment gains FDA approval for pancreatic cancer — FDA approves NovoCure treatment

The U.S. Food and Drug Administration has approved NovoCure Ltd's treatment for adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.

This development is a significant milestone for NovoCure Ltd as it expands its treatment portfolio for challenging cancer types. Pancreatic cancer remains one of the most aggressive forms, and this approval may offer new hope for patients and healthcare providers alike.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Blockchain nation in crisis: How a power struggle split Liberland

By Pavlo Kot
16 hours ago

Blockchain nation in crisis: How a power struggle split Liberland

Editors' Picks

Shifting priorities: Governments back mining as businesses turn to AI

By Eugene Komchuk
Yesterday

Shifting priorities: Governments back mining as businesses turn to AI

Editors' Picks

Intel's comeback: Apple, Trump and the AI bet

By Mikhail Vnuchkov
18.06.2026

Intel's comeback: Apple, Trump and the AI bet

Editors' Picks

All Editors' Top Picks

Latest NovoCure News

NovoCure Ltd unveils topline results from Phase 3 TRIDENT trial

By Andrey Mastykin
18.06.2026

NovoCure Ltd unveils topline results from Phase 3 TRIDENT trial

Companies

NovoCure Ltd reports first quarter 2026 earnings performance

By Anastasiia Chabaniuk
30.04.2026

NovoCure Ltd reports first quarter 2026 earnings performance

Companies

NovoCure Ltd to release first quarter 2026 financial results on April 30

By Olesia Kramarenko
01.04.2026

NovoCure Ltd to release first quarter 2026 financial results on April 30

Companies

All NovoCure News

Pavlo Kot
16 hours ago

Blockchain nation in crisis: How a power struggle split Liberland

Eugene Komchuk
Yesterday

Shifting priorities: Governments back mining as businesses turn to AI

Mikhail Vnuchkov
18.06.2026

Intel's comeback: Apple, Trump and the AI bet

Oleg Tkachenko
17.06.2026

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Anastasiia Chabaniuk
16.06.2026

Toncoin becomes Gram: Why Durov restored token's original name

Parshwa Turakhiya
22 min ago

MRVL marks 14th consecutive green weekly candle, Jake Wujastyk notes

Daria Chernytska
37 min ago

Bobby Ong: MSUSD stablecoin loses its peg, stability questioned

Yaroslav Dmytrenko
47 min ago

Dean Baker: Crypto linked to fraud and criminal activity, Democratic NY senator implicated

Andreas Kristo
57 min ago

Silver review covers past and current corrections, Patrick Karim examines

Daria Chernytska
1 hour ago

Mason Versluis: Deep dive review covers HyroTrader crypto prop firm

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Pavlo Kot
16 hours ago

Blockchain nation in crisis: How a power struggle split Liberland

Blockchain nation in crisis: How a power struggle split Liberland

Andrey Mastykin
Yesterday

Iran tightens rules for Hormuz ship transit

Iran tightens rules for Hormuz ship transit

Hanna Syniavska
Yesterday

U.S.-Iran talks postponed as truce outlook dims

U.S.-Iran talks postponed as truce outlook dims

Olga Shendetskaya
Yesterday

Oil gains after new U.S.-Iran talks are called off

Oil gains after new U.S.-Iran talks are called off

Igor Krasulya
Yesterday

Goldman Sachs revises gold forecast as Fed stays hawkish

Goldman Sachs revises gold forecast as Fed stays hawkish

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft under pressure as technical picture remains weak

Anton Kharitonov
Now

Apple consolidates after AI rally as investors await new growth catalyst

Anton Kharitonov
Now

Bitcoin struggles for direction amid macroeconomic uncertainty

Anton Kharitonov
Now

WTI recovers after selloff as downside risks remain

Anton Kharitonov
Now

Natural gas maintains upward bias amid supply risks and seasonal demand

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.